Triterpenes compound extracted from cortex periplocae inhibits tumorigenesis of esophageal cancer Eca109 cells in nude mice and related mechanisms

Chinese Journal of Cancer Biotherapy

Volumn 17, Issue 6, 2010, Pages 620-624

  Wang, Li Fang ^a   Liu, Li Hua ^a   Ma, Yu Mei ^a   Meng, Fan Ru ^a   Shan, Tie Qiang ^a   Shan, Bao En ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Eca109 cell; Esophageal cancer; Survivin; Triterpenes compound extracted from cortex periplocae

Indexed keywords

SURVIVIN; TRITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GRAFT; CARCINOGENESIS; CELL DEATH; CELL INFILTRATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGUS CANCER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MONITORING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SOYBEAN; TUMOR CELL; TUMOR GROWTH; WESTERN BLOTTING;

EID: 78650873383     PISSN: 1007385X     EISSN: None     Source Type: Journal    
DOI: 10.3872/j.issn.1007-385X.2010.06.006     Document Type: Article

References (20)

1. Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, et al. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer[J]. Ann Thorac Surg, 2010, 90(3): 892-898.
2. Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, Milan G, et al. Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma[J]. Int J Cancer, 2006, 119(7): 1717-1722.
3. Hoffmann AC, Vallböhmer D, Grimminger P, Metzger R, Prenzel KL, Hoelscher AH, et al. Preoperative survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma[J]. Pharmacogenomics, 2010, 11(3): 341-347.
4. Luker KE, Luker GD. Bioluminescence imaging of reporter mice for studies of infection and inflammation[J]. Antiviral Res, 2010, 86(1): 93-100.
5. Sun W, Yang J. Functional mechanisms for human tumor suppressors[J]. J Cancer, 2010, 15(1): 136-140.
6. Meng H, Lu C, Mabuchi H, Tanigawa N. Prognostic significance and different properties of survivin splicing variants in gastric cancer[J]. Cancer Lett, 2004, 216(2): 147-155.
7. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions[J]. J Cell Mol Med, 2005, 9(2): 360-372.
8. Grimminger P, Vallböhmer D, Hoffmann A, Schulte C, Bollschweiler E, Schneider PM, et al. Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer [J]. J Surg Oncol, 2009, 100(6): 447-451.
9. Mamori S, Kahara F, Ohnishi K, Takeda A, Higashida A, Ashida C, et al. Survivin expression in primary malignant melanoma of the esophagus[J]. Scand J Gastroenterol, 2009, 44(12): 1497-1498.
10. Feng YB, Lin DC, Shi ZZ, Wang XC, Shen XM, Zhang Y, et al. Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma[J]. Int J Cancer, 2009, 124(3): 578-588.
11. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus[J]. J Clin Invest, 2001, 108(7): 981-990.
12. Wang Y, Zhu H, Quan L, Zhou C, Bai J, Zhang G, et al. Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells[J]. Cancer Biol Ther, 2005, 4(9): 974-978.